Branched-chain amino acid metabolism: From rare Mendelian diseases to more common disorders

Human Molecular Genetics

Volumn 23, Issue R1, 2014, Pages

  Burrage, Lindsay C ^a   Nagamani, Sandesh C S ^a   Campeau, Philippe M ^b   Lee, Brendan H ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOISOVALERATE DEHYDROGENASE (LIPOAMIDE); BRANCHED CHAIN AMINO ACID;

ANIMAL; DISEASE MODEL; HUMAN; LIVER TRANSPLANTATION; MAPLE SYRUP URINE DISEASE; METABOLISM; PATHOPHYSIOLOGY;

3-METHYL-2-OXOBUTANOATE DEHYDROGENASE (LIPOAMIDE); AMINO ACIDS, BRANCHED-CHAIN; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LIVER TRANSPLANTATION; MAPLE SYRUP URINE DISEASE;

EID: 84906839103     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu123     Document Type: Article

References (107)

1. Brosnan, J.T. and Brosnan, M.E. (2006) Branched-chain amino acids: enzyme and substrate regulation. J. Nutr., 136, 207S-211S.
2. Harper, A.E., Miller, R.H. and Block, K.P. (1984) Branched-chain amino acid metabolism. Annu. Rev. Nutr., 4, 409-454.
3. Wahren, J., Felig, P. and Hagenfeldt, L. (1976) Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. J. Clin. Invest., 57, 987-999.
4. Dancis, J., Levitz, M., Miller, S. and Westall, R.G. (1959) Maple syrup urine disease. Br. Med. J., 1, 91-93.
5. Menkes, J.H. (1959) Maple syrup disease; isolation and identification of organic acids in the urine. Pediatrics, 23, 348-353.
6. Menkes, J.H., Hurst, P.L. and Craig, J.M. (1954) A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance. Pediatrics, 14, 462-467.
7. Naylor, E.W. and Guthrie, R. (1978) Newborn screening for maple syrup urine disease (branched-chain ketoaciduria). Pediatrics, 61, 262-266.
8. Puffenberger, E.G. (2003) Genetic heritage of the Old Order Mennonites of southeastern Pennsylvania. Am. J. Med. Genet. C Sem. Med. Genet., 121C, 18-31.
9. Chuang, D.T., Shih, V.E. and Max Wynn, R.R. (2013) Maple Syrup Urine Disease (Branched-Chain Ketoaciduria). In: Valle D., Beaudet A.L., Vogelstein B., Kinzler K.W., Antonarakis S.E., Ballabio A., Gibson K., Mitchell G. eds.OMMBID-The Online Metabolic and Molecular Bases of Inherited Diseases. McGraw-Hill, New York. http://ommbid.mhmedical. com.ezproxyhost.library.tmc.edu/content.aspx?bookid=474&Sectionid=45374075. Last accessed on 17 February 2014.
10. Indo, Y., Akaboshi, I., Nobukuni, Y., Endo, F. and Matsuda, I. (1988) Maple syrup urine disease: a possible biochemical basis for the clinical heterogeneity. Hum. Genet., 80, 6-10.
11. Chuang, J.L., Wynn, R.M., Moss, C.C., Song, J.L., Li, J., Awad, N., Mandel, H. and Chuang, D.T. (2004) Structural and biochemical basis for novel mutations in homozygous Israeli maple syrup urine disease patients: a proposed mechanism for the thiamin-responsive phenotype. J. Biol. Chem., 279, 17792-17800.
12. Scriver, C.R., Mackenzie, S., Clow, C.L. and Delvin, E. (1971) Thiamine-responsive maple-syrup-urine disease. Lancet, 1, 310-312.
13. Robinson, B.H., Taylor, J. and Sherwood, W.G. (1977) Deficiency of dihydrolipoyl dehydrogenase (a component of the pyruvate and alpha-ketoglutarate dehydrogenase complexes): a cause of congenital chronic lactic acidosis in infancy. Pediatr. Res., 11, 1198-1202.
14. Clow, C.L., Reade, T.M. and Scriver, C.R. (1981) Outcome of early and long-term management of classical maple syrup urine disease. Pediatrics, 68, 856-862.
15. Puliyanda, D.P., Harmon, W.E., Peterschmitt, M.J., Irons, M. and Somers, M.J. (2002) Utility of hemodialysis in maple syrup urine disease. Pediatr. Nephrol., 17, 239-242.
16. Rutledge, S.L., Havens, P.L., Haymond, M.W., McLean, R.H., Kan, J.S. and Brusilow, S.W. (1990) Neonatalhemodialysis: effective therapy for the encephalopathy of inborn errors of metabolism. J. Pediatr., 116, 125-128.
17. Schaefer, F., Straube, E., Oh, J., Mehls, O. and Mayatepek, E. (1999) Dialysis in neonates with inborn errors of metabolism. Nephrol. Dial. Transpl., 14, 910-918.
18. Hilliges, C., Awiszus, D. and Wendel, U. (1993) Intellectual performance of children with maple syrup urine disease. Eur. J. Pediatr., 152, 144-147.
19. Kaplan, P., Mazur, A., Field, M., Berlin, J.A., Berry, G.T., Heidenreich, R., Yudkoff, M. and Segal, S. (1991) Intellectual outcome in children with maple syrup urine disease. J. Pediatr., 119, 46-50.
20. American College of Medical Geneticsa Newburn Screening Express Group (2006) Newborn screening: toward a uniform screening panel and system. Genet. Med., 8 (Suppl. 1), 1S-252S.
21. Bhattacharya, K., Khalili, V., Wiley, V., Carpenter, K. and Wilcken, B. (2006) Newborn screeningmayfail to identify intermediate forms of maple syrup urine disease. J. Inherited Metabolic Dis., 29, 586.
22. Muelly, E.R., Moore, G.J., Bunce, S.C., Mack, J., Bigler, D.C., Morton, D.H. and Strauss, K.A. (2013) Biochemical correlates of neuropsychiatric illness in maple syrup urine disease. J. Clin. Invest., 123, 1809-1820.
23. Hoffmann, B., Helbling, C., Schadewaldt, P. and Wendel, U. (2006) Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD. Pediatr. Res., 59, 17-20.
24. Bodner-Leidecker, A., Wendel, U., Saudubray, J.M. and Schadewaldt, P. (2000) Branched-chain L-amino acid metabolism in classical maple syrup urine disease after orthotopic liver transplantation. J. Inherited Metabolic Dis., 23, 805-818.
25. Wendel, U., Saudubray, J.M., Bodner, A. and Schadewaldt, P. (1999) Liver transplantation in maple syrup urine disease. Eur. J. Pediatr., 158 (Suppl 2), S60-S64.
26. Strauss, K.A., Mazariegos, G.V., Sindhi, R., Squires, R., Finegold, D.N., Vockley, G., Robinson, D.L., Hendrickson, C., Virji, M., Cropcho, L. et al. (2006) Elective liver transplantation for the treatment of classical maple syrup urine disease. Am. J. Transpl., 6, 557-564.
27. Mazariegos, G.V., Morton, D.H., Sindhi, R., Soltys, K., Nayyar, N., Bond, G., Shellmer, D., Shneider, B., Vockley, J. and Strauss, K.A. (2012) Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. J. Pediatr., 160, 116-121 e111.
28. Shellmer, D.A., DeVito Dabbs, A., Dew, M.A., Noll, R.B., Feldman, H., Strauss, K.A., Morton, D.H., Vockley, J. and Mazariegos, G.V. (2011) Cognitive and adaptive functioning after liver transplantation for maple syrup urine disease: a case series. Pediatr. Transpl., 15, 58-64.
29. Suryawan, A., Hawes, J.W., Harris, R.A., Shimomura, Y., Jenkins, A.E. and Hutson, S.M. (1998) A molecular model of human branched-chain amino acid metabolism. Am. J. Clin. Nutr., 68, 72-81.
30. Badell, I.R., Hanish, S.I., Hughes, C.B., Hewitt, W.R., Chung, R.T., Spivey, J.R. and Knechtle, S.J. (2013) Domino liver transplantation in maple syrup urine disease: a case report and review of the literature. Transpl. Proc., 45, 806-809.
31. Barshop, B.A. and Khanna, A. (2005) Domino hepatic transplantation in maple syrup urine disease. New England J. Med., 353, 2410-2411.
32. Khanna, A., Hart, M., Nyhan, W.L., Hassanein, T., Panyard-Davis, J. and Barshop, B.A. (2006) Domino liver transplantation in maple syrup urine disease. Liver Transpl., 12, 876-882.
33. Arnon, R., Kerkar, N., Davis, M.K., Anand, R., Yin, W. and Gonzalez-Peralta, R.P. (2010) Liver transplantation in children with metabolic diseases: the studies of pediatric liver transplantation experience. Pediatr. Transpl., 14, 796-805.
34. Skvorak, K.J., Hager, E.J., Arning, E., Bottiglieri, T., Paul, H.S., Strom, S.C., Homanics, G.E., Sun, Q., Jansen, E.E., Jakobs, C. et al. (2009) Hepatocyte transplantation (HTx) corrects selected neurometabolic abnormalities in murine intermediate maple syrup urine disease (iMSUD). Biochim. Biophys. Acta, 1792, 1004-1010.
35. Skvorak, K.J., Paul, H.S., Dorko, K., Marongiu, F., Ellis, E., Chace, D., Ferguson, C., Gibson, K.M., Homanics, G.E. and Strom, S.C. (2009) Hepatocyte transplantation improves phenotype and extends survival in a murine model of intermediate maple syrup urine disease. Mol. Ther., 17, 1266-1273.
36. Homanics, G.E., Skvorak, K., Ferguson, C., Watkins, S. and Paul, H.S. (2006) Production and characterization of murine models of classic and intermediate maple syrup urine disease. BMC Med. Genet., 7, 33.
37. Skvorak, K.J., Dorko, K., Marongiu, F., Tahan, V., Hansel, M.C., Gramignoli, R., Arning, E., Bottiglieri, T., Gibson, K.M. and Strom, S.C. (2013) Improved amino acid, bioenergetic metabolite and neurotransmitter profiles following human amnion epithelial cell transplant in intermediate maple syrup urine disease mice. Mol. Genet. Metab., 109, 132-138.
38. Skvorak, K.J., Dorko, K., Marongiu, F., Tahan, V., Hansel, M.C., Gramignoli, R., Gibson, K.M. and Strom, S.C. (2013) Placental stem cell correction of murine intermediate maple syrup urine disease. Hepatology, 57, 1017-1023.
39. Herman, M.A., She, P., Peroni, O.D., Lynch, C.J. and Kahn, B.B. (2010) Adipose tissue branched chain amino acid (BCAA) metabolism modulates circulating BCAA levels. J. Biol. Chem., 285, 11348-11356.
40. Zimmerman, H.A., Olson, K.C., Chen, G. and Lynch, C.J. (2013) Adipose transplant for inborn errors of branched chain amino acid metabolism in mice. Mol. Genet. Metab., 109, 345-353.
41. Simon, E., Schwarz, M. and Wendel, U. (2007) Social outcome in adults with maple syrup urine disease (MSUD). J. Inherited Metabolic Dis., 30, 264.
42. Packman, W., Mehta, I., Rafie, S., Mehta, J., Naldi, M. and Mooney, K.H. (2012) Young adults with MSUD and their transition to adulthood: psychosocial issues. J. Genet. Couns., 21, 692-703.
43. Yudkoff, M., Daikhin, Y., Nissim, I., Horyn, O., Luhovyy,B. and Lazarow, A. (2005) Brain amino acid requirements and toxicity: the example of leucine. J. Nutr., 135, 1531S-1538S.
44. Sitta, A., Ribas, G.S., Mescka, C.P., Barschak, A.G., Wajner, M. and Vargas, C.R. (2013) Neurological damage in MSUD: the role of oxidative stress. Cell. Mol. Neurobiol., 34, 157-165.
45. Oldendorf, W.H. and Szabo, J. (1976) Amino acid assignment to one of three blood-brain barrier amino acid carriers. Am. J. Physiol., 230, 94-98.
46. Strauss, K.A., Wardley, B., Robinson, D., Hendrickson, C., Rider, N.L., Puffenberger, E.G., Shellmer, D., Moser, A.B. and Morton, D.H. (2010) Classical maple syrup urine disease and brain development: principles of management and formula design. Mol. Genet. Metab., 99, 333-345.
47. Zinnanti, W.J., Lazovic, J., Griffin, K., Skvorak, K.J., Paul, H.S., Homanics, G.E., Bewley, M.C., Cheng, K.C., Lanoue, K.F. and Flanagan, J.M. (2009) Dual mechanismof brain injury and novel treatment strategy in maple syrup urine disease. Brain, 132, 903-918.
48. Tews, J.K., Repa, J.J. and Harper, A.E. (1991) Branched-chain and other amino acids in tissues of rats fed leucine-limiting amino acid diets containing norleucine. J. Nutr., 121, 364-378.
49. Fontella, F.U., Gassen, E., Pulrolnik, V., Wannmacher, C.M., Klein, A.B., Wajner, M. and Dutra-Filho, C.S. (2002) Stimulation of lipid peroxidation in vitro in rat brain by the metabolites accumulating in maple syrup urine disease. Metabolic Brain Dis., 17, 47-54.
50. Bridi, R., Araldi, J., Sgarbi, M.B., Testa, C.G., Durigon, K., Wajner, M. and Dutra-Filho, C.S. (2003) Induction of oxidative stress in rat brain by the metabolites accumulating in maple syrup urine disease. Int. J. Dev. Neurosci., 21, 327-332.
51. Funchal, C., Latini, A., Jacques-Silva, M.C., Dos Santos, A.Q., Buzin, L., Gottfried, C., Wajner, M. and Pessoa-Pureur, R. (2006) Morphological alterations and induction of oxidative stress in glial cells caused by the branched-chain alpha-keto acids accumulating in maple syrup urine disease. Neurochem. Int., 49, 640-650.
52. Barschak, A.G., Sitta, A., Deon, M., de Oliveira, M.H., Haeser, A., Dutra-Filho, C.S., Wajner, M. and Vargas, C.R. (2006) Evidence that oxidative stress is increased in plasma from patients with maple syrup urine disease. Metabolic Brain Dis., 21, 279-286.
53. Barschak, A.G., Sitta, A., Deon, M., Barden, A.T., Dutra-Filho, C.S., Wajner, M. and Vargas, C.R. (2008) Oxidative stress in plasma from maple syrup urine disease patients during treatment. Metabolic Brain Dis., 23, 71-80.
54. Mescka, C.P., Wayhs, C.A., Vanzin, C.S., Biancini, G.B., Guerreiro, G., Manfredini, V., Souza, C., Wajner, M., Dutra-Filho, C.S. and Vargas, C.R. (2013) Protein and lipid damage in maple syrup urine disease patients: l-carnitine effect. Int. J. Dev. Neurosci., 31, 21-24.
55. Mescka, C., Moraes, T., Rosa, A., Mazzola, P., Piccoli, B., Jacques, C., Dalazen, G., Coelho, J., Cortes, M., Terra, M. et al. (2011) In vivo neuroprotective effect of L-carnitine against oxidative stress in maple syrup urine disease. Metabolic Brain Dis., 26, 21-28.
56. Patel, M.S., Auerbach, V.H., Grover, W.D. and Wilbur, D.O. (1973) Effect of the branched-chain alpha-keto acids on pyruvate metabolism by homogenates of human brain. J. Neurochem., 20, 1793-1796.
57. Patel, M.S. (1974) Inhibition by the branched-chain 2-oxo acids of the 2-oxoglutarate dehydrogenase complex in developing rat and human brain. Biochem. J., 144, 91-97.
58. Amaral, A.U., Leipnitz, G., Fernandes, C.G., Seminotti, B., Schuck, P.F. and Wajner, M. (2010) Alpha-ketoisocaproic acid and leucine provoke mitochondrial bioenergetic dysfunction in rat brain. Brain Res., 1324, 75-84.
59. Ribeiro, C.A., Sgaravatti, A.M., Rosa, R.B., Schuck, P.F., Grando, V., Schmidt, A.L., Ferreira, G.C., Perry, M.L., Dutra-Filho, C.S. and Wajner, M. (2008) Inhibition of brain energy metabolism by the branched-chain amino acids accumulating in maple syrup urine disease. Neurochem. Res., 33, 114-124.
60. Sgaravatti, A.M., Rosa, R.B., Schuck, P.F., Ribeiro, C.A., Wannmacher, C.M., Wyse, A.T., Dutra-Filho, C.S. and Wajner, M. (2003) Inhibition of brain energy metabolism by the alpha-keto acids accumulating in maple syrup urine disease. Biochim. Biophys. Acta, 1639, 232-238.
61. Shestopalov, A.I. and Kristal, B.S. (2007) Branched chain keto-acids exert biphasic effects on alpha-ketoglutarate-stimulated respiration in intact rat liver mitochondria. Neurochem. Res., 32, 947-951.
62. Howell, R.K. and Lee, M. (1963) Influence of alpha-ketoacids on the respiration of brain in vitro. Proc. Soc. Exp. Biol. Med., 113, 660-663.
63. Pilla, C., de Oliveira Cardozo, R.F., Dutra-Filho, C.S., Wyse, A.T., Wajner, M. and Wannmacher, C.M. (2003) Effect of leucine administration on creatine kinase activity in rat brain. Metabolic Brain Dis., 18, 17-25.
64. Yudkoff, M., Daikhin, Y., Lin, Z.P., Nissim, I., Stern, J. and Pleasure, D. (1994) Interrelationships of leucine and glutamate metabolism in cultured astrocytes. J. Neurochem., 62, 1192-1202.
65. Zielke, H.R., Huang, Y., Baab, P.J., Collins, R.M. Jr, Zielke, C.L. and Tildon, J.T. (1997) Effect of alpha-ketoisocaproate and leucine on the in vivo oxidation of glutamate and glutamine in the rat brain. Neurochem. Res., 22, 1159-1164.
66. Gibson, G.E. and Blass, J.P. (1976) Inhibition of acetylcholine synthesis and of carbohydrate utilization by maple-syrup-urine disease metabolites. J. Neurochem., 26, 1073-1078.
67. Jouvet, P., Rustin, P., Taylor, D.L., Pocock, J.M., Felderhoff-Mueser, U., Mazarakis, N.D., Sarraf, C., Joashi, U., Kozma, M., Greenwood, K. et al. (2000) Branched chain amino acids induce apoptosis in neural cells without mitochondrial membrane depolarization or cytochrome c release: implications for neurological impairment associated with maple syrup urine disease. Mol. Biol. Cell, 11, 1919-1932.
68. Scaini, G., Mello-Santos, L.M., Furlanetto, C.B., Jeremias, I.C., Mina, F., Schuck, P.F., Ferreira, G.C., Kist, L.W., Pereira, T.C., Bogo, M.R. et al. (2013) Acute and chronic administration of the branched-chain amino acids decreases nerve growth factor in rat hippocampus. Mol. Neurobiol., 48, 581-589.
69. Scaini, G., Comim, C.M., Oliveira, G.M., Pasquali, M.A., Quevedo, J., Gelain, D.P., Moreira, J.C., Schuck, P.F., Ferreira, G.C., Bogo, M.R. et al. (2013) Chronic administration of branched-chain amino acids impairs spatial memory and increases brain-derived neurotrophic factor in a rat model. J. Inherited Metabolic Dis., 36, 721-730.
70. Funchal, C., Tramontina, F., Quincozes dos Santos, A., Fraga de Souza, D., Goncalves, C.A., Pessoa-Pureur, R. and Wajner, M. (2007) Effect of the branched-chain alpha-keto acids accumulating in maple syrup urine disease on S100B release from glial cells. J. Neurol. Sci., 260, 87-94.
71. Funchal, C., de Lima Pelaez, P., Loureiro, S.O., Vivian, L., Dall Bello Pessutto, F., de Almeida, L.M., Tchernin Wofchuk, S., Wajner, M. and Pessoa Pureur, R. (2002) Alpha-Ketoisocaproic acid regulates phosphorylation of intermediate filaments in postnatal rat cortical slices through ionotropic glutamatergic receptors. Brain Res., 139, 267-276.
72. Funchal, C., Dall Bello Pessutto, F., de Almeida, L.M., de Lima Pelaez, P., Loureiro, S.O., Vivian, L., Wajner, M. and Pessoa-Pureur, R. (2004) Alpha-keto-beta-methylvaleric acid increases the in vitro phosphorylation of intermediate filaments in cerebral cortex of young rats through the gabaergic system. J. Neurol. Sci., 217, 17-24.
73. Dwivedi, C., James, E.C. and Parmar, S.S. (1986) Effects of abnormal metabolites of maple syrup urine disease on neurotransmitter receptor binding. Biochem. Med. Metabolic Biol., 35, 275-278.
74. Oyarzabal, A., Martinez-Pardo, M., Merinero, B., Navarrete, R., Desviat, L.R., Ugarte, M. and Rodriguez-Pombo, P. (2013) A novel regulatory defect in the branched-chain alpha-keto acid dehydrogenase complex due to a mutation in the PPM1Kgene causes a mild variant phenotype of maple syrup urine disease. Hum. Mutat., 34, 355-362.
75. Harris, R.A., Joshi, M., Jeoung, N.H. and Obayashi, M. (2005) Overview of the molecular and biochemical basis of branched-chain amino acid catabolism. J. Nutr., 135, 1527S-1530S.
76. Harris, R.A., Popov, K.M., Zhao, Y. and Shimomura, Y. (1994) Regulation of branched-chain amino acid catabolism. J. Nutr., 124, 1499S-1502S.
77. Harris, R.A., Joshi, M. and Jeoung, N.H. (2004) Mechanisms responsible for regulation of branched-chain aminoacid catabolism. Biochem. Biophys. Res. Commun., 313, 391-396.
78. Batshaw, M.L., MacArthur, R.B. and Tuchman, M. (2001) Alternative pathway therapy for urea cycle disorders: twenty years later. J. Pediatr., 138, S46-S54; discussion S54-45.
79. Brusilow, S., Tinker, J. and Batshaw, M.L. (1980) Amino acid acylation: a mechanismof nitrogen excretion in inborn errors of urea synthesis. Science, 207, 659-661.
80. Brusilow, S.W. (1991) Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr. Res., 29, 147-150.
81. Burlina, A.B., Ogier, H., Korall, H. and Trefz, F.K. (2001) Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients. Mol. Genet. Metab., 72, 351-355.
82. Scaglia, F., Brunetti-Pierri, N., Kleppe, S., Marini, J., Carter, S., Garlick, P., Jahoor, F., O'Brien,W. and Lee, B. (2004) Clinical consequences of urea cycle enzyme deficiencies and potential links to arginine and nitric oxide metabolism. J. Nutr., 134, 2775S-2782S; discussion 2796S-2797S.
83. Tuchman, M., Lee, B., Lichter-Konecki, U., Summar, M.L., Yudkoff, M., Cederbaum, S.D., Kerr, D.S., Diaz, G.A., Seashore, M.R., Lee, H.S. et al. (2008) Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol. Genet. Metab., 94, 397-402.
84. Brunetti-Pierri, N., Lanpher, B., Erez, A., Ananieva, E.A., Islam, M., Marini, J.C., Sun, Q., Yu, C., Hegde, M., Li, J. et al. (2011) Phenylbutyrate therapy for maple syrup urine disease. Hum. Mol. Genet., 20, 631-640.
85. Tso, S.C., Qi, X., Gui, W.J., Chuang, J.L., Morlock, L.K., Wallace, A.L., Ahmed, K., Laxman, S., Campeau, P.M., Lee, B.H. et al. (2013) Structure-based design and mechanisms of allosteric inhibitors for mitochondrial branched-chain alpha-ketoacid dehydrogenase kinase. Proc. Natl. Acad. Sci. USA, 110, 9728-9733.
86. Novarino, G., El-Fishawy, P., Kayserili, H., Meguid, N.A., Scott, E.M., Schroth, J., Silhavy, J.L., Kara, M., Khalil, R.O., Ben-Omran, T. et al. (2012) Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science, 338, 394-397.
87. Garcia-Cazorla, A., Oyarzabal, A., Fort, J., Robles, C., Castejon, E., Ruiz-Sala, P., Bodoy, S., Merinero, B., Lopez-Sala, A., Dopazo, J. et al. (2014) Two novel mutations in the BCKDK gene (branched-chain keto-acid dehydrogenase kinase) are responsible of a neurobehavioral deficit in two pediatric unrelated patients. Hum. Mut., 35, 470-477.
88. Tonjes, M., Barbus, S., Park, Y.J.,Wang,W., Schlotter, M., Lindroth, A.M., Pleier, S.V., Bai, A.H., Karra, D., Piro, R.M. et al. (2013) BCAT1promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat. Med., 19, 901-908.
89. Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J. et al. (2009) IDH1 and IDH2 mutations in gliomas. New Engl. J. Med., 360, 765-773.
90. Adibi, S.A. (1968) Influence of dietary deprivations on plasma concentration of free amino acids of man. J. Appl. Physiol., 25, 52-57.
91. Felig, P., Marliss, E. and Cahill, G.F. Jr (1969) Plasma amino acid levels and insulin secretion in obesity. New Engl. J. Med., 281, 811-816.
92. Newgard, C.B., An, J., Bain, J.R., Muehlbauer, M.J., Stevens, R.D., Lien, L.F., Haqq, A.M., Shah, S.H., Arlotto, M., Slentz, C.A. et al. (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab., 9, 311-326.
93. Huffman, K.M., Shah, S.H., Stevens, R.D., Bain, J.R., Muehlbauer, M., Slentz, C.A., Tanner, C.J., Kuchibhatla, M., Houmard, J.A., Newgard, C.B. et al. (2009) Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diab. Care, 32, 1678-1683.
94. Tai, E.S., Tan, M.L., Stevens, R.D., Low, Y.L., Muehlbauer, M.J., Goh, D.L., Ilkayeva, O.R., Wenner, B.R., Bain, J.R., Lee, J.J. et al. (2010) Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia, 53, 757-767.
95. Shah, S.H., Bain, J.R., Muehlbauer, M.J., Stevens, R.D., Crosslin, D.R., Haynes, C., Dungan, J., Newby, L.K., Hauser, E.R., Ginsburg, G.S. et al. (2010) Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ. Cardiovasc. Genet., 3, 207-214.
96. Svetkey, L.P., Stevens, V.J., Brantley, P.J., Appel, L.J., Hollis, J.F., Loria, C.M., Vollmer, W.M., Gullion, C.M., Funk, K., Smith, P. et al. (2008) Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. JAMA, 299, 1139-1148.
97. Wang, T.J., Larson,M.G., Vasan, R.S., Cheng, S., Rhee, E.P., McCabe, E., Lewis, G.D., Fox,C.S., Jacques, P.F., Fernandez,C. et al. (2011) Metabolite profiles and the risk of developing diabetes. Nat. Med., 17, 448-453.
98. Laferrere, B., Reilly, D., Arias, S., Swerdlow, N., Gorroochurn, P., Bawa, B., Bose, M., Teixeira, J., Stevens, R.D., Wenner, B.R. et al. (2011) Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci. Transl. Med., 3, 80-82.
99. Hutton, J.C., Sener, A. and Malaisse, W.J. (1980) Interaction of branched chain amino acids and keto acids upon pancreatic islet metabolism and insulin secretion. J. Biol. Chem., 255, 7340-7346.
100. Adams, S.H. (2011) Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv. Nutr., 2, 445-456.
101. Steigmann, F., Szanto, P.B., Poulos, A., Lim, P.E. and Dubin, A. (1984) Significance of serum aminograms in diagnosis and prognosis of liver diseases. J. Clin. Gastroenterol., 6, 453-460.
102. The San-in Group of Liver surgery (1997) Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. The San-in Group of Liver Surgery. Br. J. Surg., 84, 1525-1531.
103. Habu, D., Nishiguchi, S., Nakatani, S., Kawamura, E., Lee, C., Enomoto, M., Tamori, A., Takeda, T., Tanaka, T. and Shiomi, S. (2003) Effect of oral supplementation with branched-chain amino acid granules on serum albumin level in the early stage of cirrhosis: a randomized pilot trial. Hepatol. Res., 25, 312-318.
104. Muto, Y., Sato, S., Watanabe, A., Moriwaki, H., Suzuki, K., Kato, A., Kato, M., Nakamura, T., Higuchi, K., Nishiguchi, S. et al. (2005) Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin. Gastroenterol. Hepatol., 3, 705-713.
105. Gluud, L.L., Dam, G., Borre, M., Les, I., Cordoba, J., Marchesini, G., Aagaard, N.K., Risum, N. and Vilstrup, H. (2013) Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J. Nutr., 143, 1263-1268.
106. Marchesini, G., Bianchi, G., Merli, M., Amodio, P., Panella, C., Loguercio, C., Rossi Fanelli, F. and Abbiati, R. (2003) Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology, 124, 1792-1801.
107. Kawaguchi, T., Izumi, N., Charlton, M.R. and Sata, M. (2011) Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology, 54, 1063-1070.